Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/32416
Title: Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord
Authors: S. Manochantr
Y. U-pratya
P. Kheolamai
S. Rojphisan
M. Chayosumrit
C. Tantrawatpan
A. Supokawej
S. Issaragrisil
Faculty of Medicine, Thammasat University
Mahidol University
Keywords: Medicine
Issue Date: 1-Apr-2013
Citation: Internal Medicine Journal. Vol.43, No.4 (2013), 430-439
Abstract: Background: The role of bone marrow-derived mesenchymal stromal cells (BM-MSC) in preventing the incidence and ameliorating the severity of graft-versus-host disease (GvHD) has recently been reported. However, as the collection of BM-MSC is an invasive procedure, more accessible sources of MSC are desirable. Aim: This study aimed to explore the alternative sources of MSC from amnion, placenta, Wharton's jelly and umbilical cord, which are usually discarded. Methods: MSC from those tissues were isolated using mechanical dissociation and enzymatic digestion. Their capacity for proliferation and differentiation, and ability to suppress alloreactive T-lymphocytes were studied and compared with those of BM-MSC. Results: MSC derived from amnion, placenta, Wharton's jelly and umbilical cord were similar to BM-MSC regarding the cell morphology, the immunophenotype as well as the differentiation ability. These MSC also elicited a similar degree of immunosuppression, as evidenced by the inhibition of alloreactive T-lymphocytes in the mixed lymphocyte reaction, compared with that of BM-MSC. MSC from umbilical cord and Wharton's jelly had a higher proliferative capacity, whereas those from amnion and placenta had a lower proliferative capacity compared with BM-MSC. Conclusion: The results obtained from this study suggest that MSC from amnion, placenta, Wharton's jelly and umbilical cord can therefore be potentially used for substituting BM-MSC in several therapeutic applications, including the treatment of GvHD. © 2012 Royal Australasian College of Physicians.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84875667664&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/32416
ISSN: 14455994
14440903
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.